Program
Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol
Also written as “Symbicort Turbuhaler”, “Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)” and “Budesonide/formoterol (Symbicort® Turbuhaler®)”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Drug pageBudesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 80 open or running | phase 4since Dec 17, 2007 | Oct 6, 2006 | none ahead |
| Chenpon Pharmaceutical | 10 open or running | phase 1since Aug 31, 2026 | Aug 31, 2026 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 10 open or running | phase 1since Mar 24, 2009 | Mar 24, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chenpon Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 31, 2026First study: phase 1 study in AsthmaFirst studyNCT07804303 · 30 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Chenpon Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07804303Asthma · China | 1 | Completed | Jan 22, 2024 | 30 |
How it is read
Names in the registry
- “Symbicort Turbuhaler”, 3 entries
- “Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference)”, 1 entry
- “Budesonide/formoterol (Symbicort® Turbuhaler®)”, 1 entry
- “Symbicort Turbuhaler (Budesonide/formoterol)”, 1 entry
- “Budesonide/formoterol (Symbicort Turbuhaler)”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 6 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.